Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
Ghostbusters: In a New Win for Providers, No Surprises Act Rules Struck for Allowing Ghost Rates
Last week, the federal government met its fourth loss in a challenge brought by health care and air ambulance providers against No Surprises Act (NSA) …
No Surprises Here: Providers Score Third Victory in No Surprises Act Litigation, Other Challenges to the NSA Continue
Congress enacted the No Surprises Act (NSA) in 2020 to reduce surprise medical bills and to provide a simple and fast procedure for out-of-network health …
Recent DOJ Settlement With NextGen Highlights Continued Enforcement Focus on Electronic Health Records Technology Vendors
On July 13, NextGen Healthcare Inc. (NextGen), an electronic health record (EHR) software vendor, reached an agreement with the Department of Justice …
The UPC and the UP: impact on patent portfolios, co-ownership and licensing
UPC: Jurisdiction and opt-out
The UPC Rules
Implications for Benefit Plans of the End of the COVID-19 National Emergency and Public Health Emergency
On Monday, April 10, President Biden signed a congressional resolution immediately ending the COVID-19 National Emergency and he had previously announced …
Australian High Court smooths out wrinkle in trade mark law: Reputation not relevant to ‘deceptive similarity’ test of infringement
R&W Case Alert: Fraud-Based Claims Against Private Equity Firms
In recent years, private equity (PE) firms have bought and sold more businesses, at higher prices, than ever before. This growth has raised the stakes …
Cybersecurity, Privacy and Data Protection 2022 Year in Review
The year 2022 saw a groundswell of interest in privacy rights and related legislation. Five states enacted new laws or regulations aimed at protecting a …
SCOTUS Case With Implications for Attorney-Client Privilege Between CIPOs and C-Suite
Litigation associate Mark H. Russell co-authored an IAM article titled “SCOTUS Case With Implications for Attorney-Client Privilege Between CIPOs and …
Exploring The Amgen Genus Claims Headed To High Court
Intellectual Property associate Jeffrey Coleman co-authored a Law360 article titled “Exploring The Amgen Genus Claims Headed To High Court” on Jan. 10, …
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane